ASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局

動脈網

2025/12/08

TCE賽道產業爆發，應用邊界不斷延伸，技術持續迭代。在今年的ASH年會上，維立志博的條件性激活的GPRC5D/CD3雙抗LBL-034，憑藉顛覆多發性骨髓瘤治療的潛力，入選ASH年會首場口頭彙報的首個重磅議題。ASH大會上更新的數據進一步佐證了LBL-034的顛覆力：400μg/kg劑量組中位隨訪13.1個月仍表現驚豔，高劑量組響應快速、應答比例高、緩解深度足；400-1200μg/kg劑量組客觀...

網頁鏈接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2590357391"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2590357391\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2590357391?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":false,"pubTime":"2025-12-08 14:54","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2590357391","market":"hk","top_or_hot":-1,"title":"ASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局","media":"動脈網","content":"<div>\n<p>TCE賽道產業爆發，應用邊界不斷延伸，技術持續迭代。在今年的ASH年會上，維立志博的條件性激活的GPRC5D/CD3雙抗LBL-034，憑藉顛覆多發性骨髓瘤治療的潛力，入選ASH年會首場口頭彙報的首個重磅議題。ASH大會上更新的數據進一步佐證了LBL-034的顛覆力：400μg/kg劑量組中位隨訪13.1個月仍表現驚豔，高劑量組響應快速、應答比例高、緩解深度足；400-1200μg/kg劑量組客觀...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b\">網頁鏈接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nASH伴髓外病變ORR 100%，維立志博LBL-034或改寫多發性骨髓瘤治療格局\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">動脈網</strong><span class=\"h-time small\">2025-12-08 14:54</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>TCE賽道產業爆發，應用邊界不斷延伸，技術持續迭代。在今年的ASH年會上，維立志博的條件性激活的GPRC5D/CD3雙抗LBL-034，憑藉顛覆多發性骨髓瘤治療的潛力，入選ASH年會首場口頭彙報的首個重磅議題。ASH大會上更新的數據進一步佐證了LBL-034的顛覆力：400μg/kg劑量組中位隨訪13.1個月仍表現驚豔，高劑量組響應快速、應答比例高、緩解深度足；400-1200μg/kg劑量組客觀...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b\">網頁鏈接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b\">動脈網</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"HK0000252160.HKD","symbol_name":"易方達 (香港) 中國股票股息基金A 類 (分派) 港元","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","article_id":"2590357391","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN202512081506199795e8d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2590357391","pubTimestamp":1765176840,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"TCE賽道產業爆發，應用邊界不斷延伸，技術持續迭代。在今年的ASH年會上，維立志博的條件性激活的GPRC5D/CD3雙抗LBL-034，憑藉顛覆多發性骨髓瘤治療的潛力，入選ASH年會首場口頭彙報的首個重磅議題。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"HK0000252160.HKD":"易方达 (香港) 中国股票股息基金A 类 (分派) 港元","HK0000500386.USD":"易方达 (香港) 中国股票股息基金A 类 (累积) 美元","BK1161":"生物科技","HK0000252152.HKD":"易方达 (香港) 中国股票股息基金A 类 (累积) 港元","09887":"维立志博-B"},"translate_title":"ASH with extramedullary lesions ORR 100%, Wei Lizhibo LBL-034 may rewrite the treatment landscape of multiple myeloma","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09887":1.5},"content_text":"TCE賽道產業爆發，應用邊界不斷延伸，技術持續迭代。在今年的ASH年會上，維立志博的條件性激活的GPRC5D/CD3雙抗LBL-034，憑藉顛覆多發性骨髓瘤治療的潛力，入選ASH年會首場口頭彙報的首個重磅議題。ASH大會上更新的數據進一步佐證了LBL-034的顛覆力：400μg/kg劑量組中位隨訪13.1個月仍表現驚豔，高劑量組響應快速、應答比例高、緩解深度足；400-1200μg/kg劑量組客觀緩解率（ORR）達82.5%，800μg/kg劑量組ORR率高達90.9%；400-1200μg/kg組中≥非常好的部分緩解（VGPR）為72.5%，完全緩解/嚴格意義的完全緩解（CR/sCR）率為52.5%；且80.0%的患者達到微小殘留病（MRD）陰性狀態，預示其有望帶來持久治療效果。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}